Close Menu

NEW YORK – Precision oncology-focused Revolution Medicines announced on Monday after the close of the market that it is hoping to raise approximately $158 million in net proceeds from an underwritten public offering of 4,000,000 shares of its common stock at $42.14 per share, the last reported stock price on the Nasdaq on Jan. 29.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.